George Y Wang
Examiner (ID: 4033)
Most Active Art Unit | 2871 |
Art Unit(s) | 2882, 2871 |
Total Applications | 215 |
Issued Applications | 148 |
Pending Applications | 11 |
Abandoned Applications | 56 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16948165
[patent_doc_number] => 20210206856
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST
[patent_app_type] => utility
[patent_app_number] => 16/997238
[patent_app_country] => US
[patent_app_date] => 2020-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 90961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16997238
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/997238 | TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST | Aug 18, 2020 | Pending |
Array
(
[id] => 16570690
[patent_doc_number] => 20210009696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => TRISPECIFIC ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 16/995414
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42520
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995414
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/995414 | Trispecific antagonists | Aug 16, 2020 | Issued |
Array
(
[id] => 16628785
[patent_doc_number] => 20210047438
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => Multispecific Antigen-Binding Molecules for Cell Targeting and Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 16/993721
[patent_app_country] => US
[patent_app_date] => 2020-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25461
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16993721
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/993721 | Multispecific antigen-binding molecules for cell targeting and uses thereof | Aug 13, 2020 | Issued |
Array
(
[id] => 18620441
[patent_doc_number] => 11753469
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Methods of using bispecific CD33 and CD3 binding proteins
[patent_app_type] => utility
[patent_app_number] => 16/989671
[patent_app_country] => US
[patent_app_date] => 2020-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 69
[patent_no_of_words] => 24041
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989671
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/989671 | Methods of using bispecific CD33 and CD3 binding proteins | Aug 9, 2020 | Issued |
Array
(
[id] => 16999490
[patent_doc_number] => 11078281
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-03
[patent_title] => Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
[patent_app_type] => utility
[patent_app_number] => 16/987334
[patent_app_country] => US
[patent_app_date] => 2020-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 26
[patent_no_of_words] => 11802
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987334
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/987334 | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) | Aug 5, 2020 | Issued |
Array
(
[id] => 18748365
[patent_doc_number] => 11807661
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-07
[patent_title] => Antibody fusion protein and related compositions for targeting cancer
[patent_app_type] => utility
[patent_app_number] => 16/929001
[patent_app_country] => US
[patent_app_date] => 2020-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 10970
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16929001
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/929001 | Antibody fusion protein and related compositions for targeting cancer | Jul 13, 2020 | Issued |
Array
(
[id] => 16391067
[patent_doc_number] => 20200332008
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES
[patent_app_type] => utility
[patent_app_number] => 16/924288
[patent_app_country] => US
[patent_app_date] => 2020-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18676
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16924288
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/924288 | Neutralization of inhibitory pathways in lymphocytes | Jul 8, 2020 | Issued |
Array
(
[id] => 18980166
[patent_doc_number] => 11905326
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Multispecific heavy chain antibodies binding to CD22 and CD3
[patent_app_type] => utility
[patent_app_number] => 16/900586
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 23
[patent_no_of_words] => 18574
[patent_no_of_claims] => 97
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900586
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/900586 | Multispecific heavy chain antibodies binding to CD22 and CD3 | Jun 11, 2020 | Issued |
Array
(
[id] => 16525290
[patent_doc_number] => 20200399370
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => Agents for Treatment of Claudin Expressing Cancer Diseases
[patent_app_type] => utility
[patent_app_number] => 16/898892
[patent_app_country] => US
[patent_app_date] => 2020-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898892
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/898892 | Agents for Treatment of Claudin Expressing Cancer Diseases | Jun 10, 2020 | Abandoned |
Array
(
[id] => 16635305
[patent_doc_number] => 10913800
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-09
[patent_title] => Anti-transferrin receptor antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/896995
[patent_app_country] => US
[patent_app_date] => 2020-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 27
[patent_no_of_words] => 43132
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16896995
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/896995 | Anti-transferrin receptor antibodies and uses thereof | Jun 8, 2020 | Issued |
Array
(
[id] => 18315117
[patent_doc_number] => 11629186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-18
[patent_title] => Anti-CCL8 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/895407
[patent_app_country] => US
[patent_app_date] => 2020-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 21
[patent_no_of_words] => 8432
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895407
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/895407 | Anti-CCL8 antibodies and uses thereof | Jun 7, 2020 | Issued |
Array
(
[id] => 16557211
[patent_doc_number] => 20210002359
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-07
[patent_title] => IMMUNOGLOBULIN VARIANTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/889510
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889510
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/889510 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | May 31, 2020 | Abandoned |
Array
(
[id] => 18013322
[patent_doc_number] => 11505604
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
[patent_app_type] => utility
[patent_app_number] => 16/874826
[patent_app_country] => US
[patent_app_date] => 2020-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 22
[patent_no_of_words] => 44378
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1065
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16874826
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/874826 | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer | May 14, 2020 | Issued |
Array
(
[id] => 16397303
[patent_doc_number] => 20200338161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNOTHERAPIES
[patent_app_type] => utility
[patent_app_number] => 16/867500
[patent_app_country] => US
[patent_app_date] => 2020-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4652
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867500
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/867500 | BTNL9 AND ERMAP AS NOVEL INHIBITORS OF THE IMMUNE SYSTEM FOR IMMUNOTHERAPIES | May 4, 2020 | Pending |
Array
(
[id] => 17307393
[patent_doc_number] => 11208486
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Human PD-L1 antibodies
[patent_app_type] => utility
[patent_app_number] => 17/277909
[patent_app_country] => US
[patent_app_date] => 2020-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 10
[patent_no_of_words] => 10983
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 139
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277909
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/277909 | Human PD-L1 antibodies | Apr 25, 2020 | Issued |
Array
(
[id] => 16512995
[patent_doc_number] => 20200392253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/849223
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67582
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -37
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849223
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/849223 | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES | Apr 14, 2020 | Pending |
Array
(
[id] => 18492270
[patent_doc_number] => 11697681
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-11
[patent_title] => Anti-annexin A2 monoclonal antibodies
[patent_app_type] => utility
[patent_app_number] => 16/848828
[patent_app_country] => US
[patent_app_date] => 2020-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 56
[patent_no_of_words] => 13951
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 514
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848828
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/848828 | Anti-annexin A2 monoclonal antibodies | Apr 13, 2020 | Issued |
Array
(
[id] => 16283786
[patent_doc_number] => 20200277388
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => TRISPECIFIC ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 16/845924
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42506
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 4
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845924
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/845924 | Trispecific antagonists | Apr 9, 2020 | Issued |
Array
(
[id] => 16468221
[patent_doc_number] => 20200369758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => BISPECIFIC ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/843763
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843763
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843763 | Bispecific antigen binding proteins | Apr 7, 2020 | Issued |
Array
(
[id] => 16770901
[patent_doc_number] => 10981990
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Antibody molecules to TIM-3 and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/841029
[patent_app_country] => US
[patent_app_date] => 2020-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 35
[patent_no_of_words] => 78829
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841029
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/841029 | Antibody molecules to TIM-3 and uses thereof | Apr 5, 2020 | Issued |